Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer

EP. 1: Dr Yuan on T-DXd in First-Line HER2+ Advanced/Metastatic Breast Cancer

September 30th 2025

Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.

EP. 2: Dr Yuan on Intracranial Activity With T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer

October 3rd 2025

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

EP. 3: Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer

October 23rd 2025

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

EP. 4: Dr Yuan on the DEMETHER Trial of Induction T-DXd Plus HP Maintenance in HER2+ Breast Cancer

October 30th 2025

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

EP. 5: Dr Yuan on the Potential Benefit of Upfront T-DXd in HER2+ Breast Cancer With CNS Metastases

November 6th 2025

Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.

EP. 6: Dr Yuan on the Evolving Landscape of ADCs in HER2+ Breast Cancer

November 13th 2025

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.